People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

34.82USD
31 Oct 2014
Price Change (% chg)

$-1.33 (-3.68%)
Prev Close
$36.15
Open
$36.95
Day's High
$36.95
Day's Low
$34.75
Volume
675,726
Avg. Vol
713,477
52-wk High
$39.94
52-wk Low
$27.51

Search Stocks

Greene, Barry 

Brief Biography

Mr. Barry E. Greene is an Independent Director of Acorda Therapeutics, Inc., since January 8, 2007. Mr. Greene currently serves as President and Chief Operating Officer of Alnylam Pharmaceuticals, Inc. Mr. Greene joined Alnylam in September 2003, bringing over 15 years of experience in the healthcare industry and in consulting. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of VELCADE (bortezomib) in mid-2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene’s past experiences included being Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck); Vice President Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and, partner of Andersen Consulting, responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene previously was a member of the boards of directors of Regulus Therapeutics, LLC and Intercept Pharmaceuticals, Inc. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and serves as a Senior Scholar at Duke University, Fuqua School of Business.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

3,918,020

Michael Rogers

4,352,770

Lauren Sabella

1,060,110

Andrew Blight

1,484,560

Jane Wasman

2,159,620

Enrique Carrazana

1,618,840
As Of 30 Dec 2013
Search Stocks